Novo Nordisk's CagriSema Shows Significant Weight Loss in REDEFINE 1 Trial, FDA Decision Expected Q4 2026
Novo Nordisk announced results from two post hoc analyses of its phase 3 REDEFINE 1 trial for investigational drug CagriSema 2.4 mg / 2.4 mg, a fixed-dose combination of cagrilintide and semaglutide, for adults with overweight or obesity. The analyses, presented at ObesityWeek® 2026 in Washington, DC, US, revealed that 67.8% of participants treated with CagriSema were 'early responders,' achieving at least 5% weight loss by week 8. Among these early responders, the observed mean weight loss at week 68 was 25.4%. For delayed responders, mean weight loss at week 68 was 17.8%. Additionally, 73.1% of CagriSema-treated adults reported a meaningful improvement in physical function at week 68, compared to 49.1% with placebo. The company filed a New Drug Application with the U.S. Food and Drug Administration (FDA) in December 2025 for CagriSema for weight management, with a decision anticipated in Q4 2026. Adverse events, mainly gastrointestinal, were reported in 5.9% of the CagriSema group versus 3.5% for placebo...